Arm Holdings plc vs Moderna, Inc. — how do they compare? Arm Holdings plc trades at $270.39 (market cap $287.22B), while Moderna, Inc. trades at $61.33 (market cap $24.18B). The key difference: Arm Holdings plc is far larger — about 11.9× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | MRNA | |
|---|---|---|
Market Cap | $287.22B | $24.18B |
Sector | Technology | Health |
52-Week High | $439.46 | $81.80 |
52-Week Low | $104.55 | $22.36 |
Enterprise Value | $283.79B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →